Ending hidden rebates in Medicare Part D
Dana P Goldman
![Dana P Goldman]()
Dana P Goldman
Founding Director, USC Schaeffer Institute | University Professor of Public Policy, Pharmacy, and Economics | LinkedIn Top Voice
Opponents of transparency in Medicare drug pricing argue that the hidden rebate system is good for beneficiaries -- because it keeps Part D premiums low. Erin Trish and I explain in a Stat opinion piece why we needn't worry. Most beneficiaries will be insulated from such premium increases, including the most financially vulnerable. Premiums won't increase by much anyway. Even more importantly, it stops financing Part D on the backs of those who are very sick and have to pay list prices in the doughnut hole, as Anupam Jena and I argued last summer in the Washington Post.
#drugspharmaceuticals #healthpolicy #healtheconomics #healthcareindustry #healthcarecost
We fix healthcare market access problems through clever pricing
6 年Why not adopt an ASP like semi transparent aggregated approach that provides innovative small players to compete with the larger PBMs? If you look at the price changes for ASP reimburses products versus pharmacy, it’s hard to argue that’s not a better way to control prices. Blended transparency hides individual deals but puts shared skin in the game for both manufacturers and payers.